Tenaya Therapeutics, Inc. (TNYA) Stock Price & Analysis
Tenaya Therapeutics, Inc. (TNYA) rose 2.50% to USD 0.68 as of September 9, 2026 at 14:17 UTC, according to Nexqual real-time market data.
TNYA last closed at USD 0.66; the session ranged USD 0.66–0.69 on volume of 441,409 shares. Market capitalization is $152.48M, with a 52-week range of USD 0.53–2.35 (NCM). Source: Nexqual, September 9, 2026 at 14:17 UTC.
Key Statistics (as of September 9, 2026 at 14:17 UTC)
| Price | USD 0.68 |
|---|---|
| Change | ▲ 2.50% (up) |
| Previous Close | USD 0.66 |
| Open | USD 0.67 |
| Day Range | USD 0.66 – 0.69 |
| 52-Week Range | USD 0.53 – 2.35 |
| Volume | 441,409 shares |
| Market Cap | $152.48M |
| Exchange | NCM |
Technical Analysis (TNYA)
Nexqual's technical model rates TNYA "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 9, 2026 at 14:17 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 40.89 (neutral) |
| vs SMA50 | Below (USD 0.76) |
| MACD | -0.02 (negative) |
Earnings (TNYA)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD -0.1 |
| Revenue Estimate | $802,500 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.09 vs est -0.07 ▼ miss |
| 2026-03-31 | USD -0.09 vs est -0.09 ▼ miss |
| 2025-12-31 | USD -0.12 vs est -0.12 ▲ beat |
| 2025-09-30 | USD -0.12 vs est -0.15 ▲ beat |
Source: Nexqual, September 9, 2026 at 14:17 UTC.
Financials & Fundamentals (TNYA)
| Total Revenue | $1.33M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -1882.79% |
| Profit Margin | +0.00% |
| ROE | -121.86% |
| Debt / Equity | 5.69 |
| Current Ratio | 4.52 |
| Total Cash | $78.08M |
| Total Debt | $3.95M |
| Free Cash Flow | $-32.60M |
Source: Nexqual, September 9, 2026 at 14:17 UTC.
Financial Health Score (TNYA)
Nexqual rates Tenaya Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of September 9, 2026 at 14:17 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $78M cash vs $4M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$52M |
| Efficiency | Critical — ROE -122%, ROA -47.9% |
Ownership (TNYA)
| Insider Ownership | +0.44% |
|---|---|
| Institutional Ownership | +48.88% |
| Shares Outstanding | 224.23M |
| Float | 211.68M |
| Short % of Float | +12.12% |
Source: Nexqual, September 9, 2026 at 14:17 UTC.
Leadership (TNYA)
Tenaya Therapeutics, Inc. is led by Faraz Ali (age 52), President, CEO & Director, per Nexqual as of September 9, 2026 at 14:17 UTC.
| President, CEO & Director | Faraz Ali (age 52) |
|---|---|
| Scientific Founder, Chairman of Scientific Advisory Board & Director | Deepak Srivastava (age 58) |
| CFO & Principal Accounting Officer | Eric Hyllengren (age 50) |
| Chief Technology Officer | Kee-Hong Kim (age 59) |
Major Backers & Investors (TNYA)
Notable institutional backers of Tenaya Therapeutics, Inc. include Millennium Management, Citadel, Renaissance Technologies, according to Nexqual as of September 9, 2026 at 14:17 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Millennium Management | 2.87% |
| Citadel | 2.04% |
| Renaissance Technologies | 1.91% |
| Empery Asset Management, LP | 1.72% |
| Marshall Wace LLP | 1.56% |
| GSA Capital Partners LLP | 1.19% |
| Burkehill Global Management, LP | 0.89% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.25% |
| BlackRock | 2.45% |
| Geode Capital | 0.82% |
Source: Nexqual, September 9, 2026 at 14:17 UTC.
From Tenaya Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
- Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
- The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration.
- It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALXO | ALX Oncology Holdings Inc. | USD 2 | ▼ 0.75% |
| TSHA | Taysha Gene Therapies, Inc. | USD 5.42 | ▼ 3.21% |
| IMRX | Immuneering Corporation | USD 4.7 | ▼ 2.49% |
| GLUE | Monte Rosa Therapeutics, Inc. | USD 14.56 | ▲ 5.2% |
| FDMT | 4D Molecular Therapeutics, Inc. | USD 14.32 | ▼ 4.38% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 14:17 UTC. This page is informational and not investment advice.